Helix Biopharma Corp. HBPCF
OTC PK
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 50.21% | -50.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.34% | -26.47% | |||
| Operating Income | -2.34% | 26.47% | |||
| Income Before Tax | 2.22% | 31.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.22% | 31.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.22% | 31.10% | |||
| EBIT | -2.34% | 26.47% | |||
| EBITDA | -2.48% | 26.40% | |||
| EPS Basic | 3.03% | 31.25% | |||
| Normalized Basic EPS | 2.44% | 31.67% | |||
| EPS Diluted | 3.03% | 31.25% | |||
| Normalized Diluted EPS | 2.44% | 31.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||